A New Prognostic Score Based on Cell-Mediated Immunity for Cytomegalovirus Infection After Transplantation.

Area of Science:

• Immunology
• Transplant Medicine
• Infectious Disease

Background:

• Cytomegalovirus (CMV) infection is a significant risk for transplant recipients.
• Assessing CMV-specific cell-mediated immunity (CMI) is crucial for identifying at-risk patients.
• Current clinical implementation of CMV-CMI assays like IFN-γ ELISpot faces challenges.

Purpose of the Study:

• To develop a novel CMV-CMI risk-score for predicting CMV infection in solid organ transplant (SOT) patients.
• To create an integrated prognostic system (CMV-PrognosTIC score) for quantifying CMV infection risk.
• To validate the score's clinical utility in guiding personalized preventive therapies.

Main Methods:

• Developed a CMV-CMI risk-score using the standardized T-SPOT.CMV assay targeting CMV antigens IE-1 and pp65.
• Pooled analysis of 570 kidney transplant patients and validation in 146 SOT patients.
• Integrated clinical variables (preventive therapy, age, CMV serostatus) into the score using penalized regression analysis.

Main Results:

• The CMV-CMI risk-score accurately discriminated low-, intermediate-, and high-risk patients for CMV infection (98.7% NPV, 97.2% sensitivity).
• Prospective implementation confirmed high negative predictive value and sensitivity in identifying low-risk patients.
• The global CMV-PrognosTIC model demonstrated accurate discrimination and calibration in both derivation and validation cohorts (AUCs: 0.807 and 0.719).

Conclusions:

• A robust CMV-PrognosTIC score was developed to quantify CMV infection risk in SOT recipients.
• The score can be readily implemented in clinical practice to personalize CMV preventive strategies.
• This approach aims to improve management and outcomes for transplant patients at risk of CMV infection.